secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYTOKINETICS INC (CYTK)
CIK:        0001061983
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0000950170-24-055046
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytokinetics reports positive Phase 1 data for CK-586; Phase 2 in HFpEF expected Q4 2024
--------------------------------------------------------------------------------

- Phase 1 study of CK-586 met primary safety, tolerability, PK objectives; no serious adverse events observed.
- CK-586 is a novel cardiac myosin inhibitor for heart failure with preserved ejection fraction (HFpEF).
- Phase 2 trial in HFpEF patients expected to begin in Q4 2024; based on Phase 1 safety and PK profile.
- Echocardiography showed pharmacodynamics consistent with expectations; linear PK across doses 10-600 mg.
- Aficamten, company's other cardiac myosin inhibitor, supported mechanism in non-obstructive HCM.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1061983/000095017024055046/0000950170-24-055046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1061983/000095017024055046/cytk-20240508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-055046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer